Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMAP-CAP adaptive platform trial for community-acquired pneumonia
2023-507889-89-00Phase 3Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of erythromycin lactobionate, tocilizumab, hydrocortisone, amoxicillin + clavulanate, roxithromycin and 12 more in community-acquired pneumonia (CAP), Airways Infection and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Primary composite endpoint. Planned start Feb 2016; status: authorised.
02
Drugs
erythromycin lactobionatetocilizumabhydrocortisoneamoxicillin + clavulanateroxithromycin
03
Conditions
community-acquired pneumonia (CAP)Airways Infectioncoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2023-507889-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507889-89-00.